Targeted therapy is an important anti-cancer therapy in non-small cell lung cancer (NSCLC). Pruritus are the common side-effect with gefitinib, an anti-EGFR antibody and tyrosine-kinase inhibitor. We reported case reports to confirm the effects of aprepitant, a neurokinin receptor to management of refractory rash and pruritus in Chinese malignancy population. patients showed a rapid recovery from refractory pruritus, no adverse events occurred. Weekly follow-up visits showed the pruritus were stable and no further episodes was recorded.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6389580 | PMC |
| http://dx.doi.org/10.21037/atm.2019.01.02 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effectiveness and Safety of Dupilumab for Prurigo Nodularis in China: A Multicentric and Observational Study.
Allergy
January 2025
Department of Dermatology, Tianjin Institute of Integrative Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, China.
Background: The efficacy and safety of dupilumab in patients with refractory prurigo nodularis (PN) is well established in clinical trials, but there is a lack of multicenter data regarding its effectiveness and safety in real-world settings.
Methods: Patients with moderate-to-severe PN who initiated dupilumab treatment between July 2023 and January 2024, with a follow-up period of at least 16 weeks at 10 hospitals in China were included. We used peak pruritus numeric rating scale (PP-NRS), investigator global assessment (IGA) for PN, and dermatology life quality index for adults or children (DLQI/CDLQI) to assess disease control status and quality of life impairment, and monitored adverse events to assess the safety.
Whole-exome sequencing identifies novel mutation in intrahepatic cholestasis of pregnancy: A case report and literature review.
Z Geburtshilfe Neonatol
January 2025
Department of Obstetrics and Gynecology, Sichuan University West China Second University Hospital, Chengdu, China.
Intrahepatic cholestasis of pregnancy (ICP) is a pregnancy-specific liver disease characterized by pruritus and elevated total bile acid (TBA) levels. The most serious impact of ICP is sudden unexplained intrauterine fetal death, especially when an associated TBA ≥ 100 µmol/L is confirmed.We report a case of a 27-year-old female patient with early-onset severe refractory ICP.
View Article and Find Full Text PDFEfficacy of 0.5% doxepin in coconut oil applied topically for chronic refractory pruritus: a case series from the VA Palo Alto Health Care System.
Arch Dermatol Res
January 2025
Department of Dermatology, Stanford University School of Medicine, 450 Broadway Street Pavilion B, 4th Floor, Redwood City, CA, 94063, USA.
Pediatric Mycosis Fungoides Mimicking Benign Dermatoses: A Report of a Rare Case.
Am J Case Rep
January 2025
Department of Pathology, Hospital Selayang, Batu Caves, Selangor, Malaysia.
BACKGROUND Primary cutaneous lymphomas (PCL) are a multifaceted spectrum of cutaneous T cell lymphoma (CTCL) and cutaneous B cell lymphomas (CBCL). Mycosis fungoides (MF) is a rare subset of CTCL that primarily affects adults, and its occurrence in children is exceedingly rare. Most pediatric MF manifests as hypopigmented patches resembling other benign dermatoses, causing diagnostic challenges.
View Article and Find Full Text PDFPractical Considerations for Odevixibat Treatment in Patients with Progressive Familial Intrahepatic Cholestasis: A Single-Center Case Series.
J Clin Med
December 2024
Pediatric Gastroenterology and Hepatology, University Children's Hospital Tübingen, Hoppe-Seyler Str. 1, 72076 Tübingen, Germany.
: Patients with progressive familial intrahepatic cholestasis (PFIC) experience cholestasis-associated symptoms, including severe pruritus. Odevixibat is an ileal bile acid transporter inhibitor indicated for treatment of PFIC in the European Union and for the treatment of pruritus in PFIC in the United States. The aim of the current study was to characterize the real-world effectiveness and safety of odevixibat in patients with PFIC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!